Caris Life Sciences, Inc.
CAI
$16.96
$0.825.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 112.43% | 75.85% | -- | -- | -- |
| Total Depreciation and Amortization | -46.06% | -53.76% | -- | -- | -- |
| Total Amortization of Deferred Charges | 81.50% | 81.00% | -- | -- | -- |
| Total Other Non-Cash Items | 195.65% | 1,421.67% | -- | -- | -- |
| Change in Net Operating Assets | -162.05% | -13.97% | -- | -- | -- |
| Cash from Operations | 172.73% | 133.91% | -- | -- | -- |
| Capital Expenditure | -154.53% | -92.56% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -154.53% | -130.72% | -- | -- | -- |
| Total Debt Issued | -- | -86.07% | -- | -- | -- |
| Total Debt Repaid | -25.25% | 32.48% | -- | -- | -- |
| Issuance of Common Stock | 19,347.42% | 34,938.95% | -- | -- | -- |
| Repurchase of Common Stock | -84,890.91% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -14.69% | -35.98% | -- | -- | -- |
| Cash from Financing | 45,136.76% | 232.01% | -- | -- | -- |
| Foreign Exchange rate Adjustments | 11,700.00% | 3,350.00% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 474.32% | 9,026.22% | -- | -- | -- |